开云app官网登录入口网页版-官方正版

#结果公布#

126篇内容 | 2524人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2004465, encodeId=a7972004465e5, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=NEJM Evid：固定疗程的伊布替尼联合维奈克拉（Ibr+Ven）一线治疗慢性淋巴细胞白血病结果公布（GLOW研究）, objectType=article, longId=731593, objectId=2592e3159385, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2592e3159385, replyNumber=0, likeNumber=77, createdTime=2023-01-10, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2592e3159385, moduleTitle=NEJM Evid：固定疗程的伊布替尼联合维奈克拉（Ibr+Ven）一线治疗慢性淋巴细胞白血病结果公布（GLOW研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2592e3159385)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004460, encodeId=f313200446048, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=Nat Med：两项多格列艾汀的III期研究结果公布，降糖作用显著且长期持续, objectType=article, longId=726861, objectId=e4bce268618c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4bce268618c, replyNumber=0, likeNumber=113, createdTime=2022-07-25, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4bce268618c, moduleTitle=Nat Med：两项多格列艾汀的III期研究结果公布，降糖作用显著且长期持续, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e4bce268618c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004462, encodeId=0b1020044626c, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=猴痘病毒最新基因测序结果公布，近似于英国三年前毒株, objectType=article, longId=727862, objectId=cb7fe278629e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb7fe278629e, replyNumber=0, likeNumber=75, createdTime=2022-12-27, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb7fe278629e, moduleTitle=猴痘病毒最新基因测序结果公布，近似于英国三年前毒株, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cb7fe278629e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004458, encodeId=66392004458e5, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=NEJM：艾伏尼布联合阿扎胞苷治疗IDH1突变AML的3期研究结果公布，患者获益显著, objectType=article, longId=724783, objectId=51e5e2478377, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51e5e2478377, replyNumber=0, likeNumber=80, createdTime=2023-02-21, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51e5e2478377, moduleTitle=NEJM：艾伏尼布联合阿扎胞苷治疗IDH1突变AML的3期研究结果公布，患者获益显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=51e5e2478377)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004461, encodeId=79d220044617c, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=JCO：阿美替尼对比吉非替尼对EGFR突变NSCLC一线治疗结果公布（AENEAS研究）, objectType=article, longId=727335, objectId=1e0ee27335dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e0ee27335dd, replyNumber=0, likeNumber=80, createdTime=2022-09-15, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e0ee27335dd, moduleTitle=JCO：阿美替尼对比吉非替尼对EGFR突变NSCLC一线治疗结果公布（AENEAS研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1e0ee27335dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004456, encodeId=55ec20044560e, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=Nature子刊：AAV病毒基因治疗艾滋病的首次临床试验结果公布, objectType=article, longId=724128, objectId=a7d5e2412810, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7d5e2412810, replyNumber=0, likeNumber=95, createdTime=2022-11-12, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7d5e2412810, moduleTitle=Nature子刊：AAV病毒基因治疗艾滋病的首次临床试验结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a7d5e2412810)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004464, encodeId=c58c200446479, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=JACC子刊：中山医院结构团队的两项中国原创器械研究结果公布, objectType=article, longId=729879, objectId=e41ae2987936, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e41ae2987936, replyNumber=0, likeNumber=137, createdTime=2022-08-13, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e41ae2987936, moduleTitle=JACC子刊：中山医院结构团队的两项中国原创器械研究结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e41ae2987936)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004455, encodeId=59a8200445562, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=AACR 2022：度伐利尤单抗和和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的结果公布 (KGOG 3046/TRU-D), objectType=article, longId=724029, objectId=ae71e2402901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae71e2402901, replyNumber=0, likeNumber=93, createdTime=2022-12-16, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae71e2402901, moduleTitle=AACR 2022：度伐利尤单抗和和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的结果公布 (KGOG 3046/TRU-D), moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ae71e2402901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004463, encodeId=66a820044638e, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）, objectType=article, longId=729571, objectId=1e09e2957129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e09e2957129, replyNumber=0, likeNumber=93, createdTime=2023-01-16, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e09e2957129, moduleTitle=NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1e09e2957129)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004449, encodeId=2fb7200444986, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=全球植物源性COVID-19疫苗3期结果公布：对变异毒株总体效力为71%！, objectType=article, longId=221739, objectId=1cac221e396d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1cac221e396d, replyNumber=0, likeNumber=72, createdTime=2022-07-01, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1cac221e396d, moduleTitle=全球植物源性COVID-19疫苗3期结果公布：对变异毒株总体效力为71%！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1cac221e396d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004457, encodeId=813b200445e1f, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=全球首个二价新冠疫苗2/3期临床结果公布，有效性是当前新冠疫苗的2倍多，秋季开打, objectType=article, longId=724738, objectId=d268e2473848, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d268e2473848, replyNumber=0, likeNumber=84, createdTime=2022-06-22, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d268e2473848, moduleTitle=全球首个二价新冠疫苗2/3期临床结果公布，有效性是当前新冠疫苗的2倍多，秋季开打, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d268e2473848)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004451, encodeId=ad0920044510d, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=Lancet microb：国产新冠mRNA疫苗临床I期结果公布，10个关键信息披露进展, objectType=article, longId=294845, objectId=815d29484541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=815d29484541, replyNumber=0, likeNumber=89, createdTime=2022-10-27, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=815d29484541, moduleTitle=Lancet microb：国产新冠mRNA疫苗临床I期结果公布，10个关键信息披露进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=815d29484541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004454, encodeId=b1062004454d2, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, objectType=article, longId=724027, objectId=af24e240278a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af24e240278a, replyNumber=0, likeNumber=89, createdTime=2022-06-24, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af24e240278a, moduleTitle=AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=af24e240278a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004453, encodeId=75fc200445344, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=AACR 2022：第四代EGFR抑制剂BLU-945治疗晚期耐药的NSCLC早期结果公布, objectType=article, longId=724026, objectId=c4f1e2402624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4f1e2402624, replyNumber=0, likeNumber=169, createdTime=2022-04-23, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4f1e2402624, moduleTitle=AACR 2022：第四代EGFR抑制剂BLU-945治疗晚期耐药的NSCLC早期结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c4f1e2402624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004450, encodeId=65422004450f9, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=公开通报：上百人被处理，涉及复旦、首医！35起医学科研诚信案件调查处理结果公布, objectType=article, longId=293310, objectId=79f3293310c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79f3293310c0, replyNumber=0, likeNumber=86, createdTime=2022-10-25, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79f3293310c0, moduleTitle=公开通报：上百人被处理，涉及复旦、首医！35起医学科研诚信案件调查处理结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=79f3293310c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004443, encodeId=0db520044434b, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=2021年国自然基金结果公布了！资助45681项！你中了吗？, objectType=article, longId=215962, objectId=fed0215962bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fed0215962bc, replyNumber=0, likeNumber=104, createdTime=2022-02-09, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fed0215962bc, moduleTitle=2021年国自然基金结果公布了！资助45681项！你中了吗？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fed0215962bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004452, encodeId=4e062004452fc, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=世界「人类故意感染新冠」试验结果公布！鼻腔注入病毒，大多数人3个月内自愈, objectType=article, longId=295272, objectId=f7422952e26c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7422952e26c, replyNumber=0, likeNumber=81, createdTime=2022-04-05, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7422952e26c, moduleTitle=世界「人类故意感染新冠」试验结果公布！鼻腔注入病毒，大多数人3个月内自愈, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f7422952e26c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004441, encodeId=e160200444170, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=2021年8月6日简报：国内多地出现新增病例，无症状感染比例占1/3；FDA制订新冠疫苗加强针计划，中国承诺向国际出口20亿剂疫苗，多款疫苗真实世界研究结果公布, objectType=article, longId=215383, objectId=d0262153839e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0262153839e, replyNumber=0, likeNumber=94, createdTime=2022-02-10, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0262153839e, moduleTitle=2021年8月6日简报：国内多地出现新增病例，无症状感染比例占1/3；FDA制订新冠疫苗加强针计划，中国承诺向国际出口20亿剂疫苗，多款疫苗真实世界研究结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d0262153839e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004433, encodeId=659020044336e, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=Nutrition 2021速递：孕期保持健康的研究结果公布, objectType=article, longId=212476, objectId=51232124e654, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51232124e654, replyNumber=0, likeNumber=114, createdTime=2021-08-27, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51232124e654, moduleTitle=Nutrition 2021速递：孕期保持健康的研究结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=51232124e654)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2004459, encodeId=20a1200445988, content=<a href='/topic/show?id=54ebe8621cf' target=_blank style='color:#2F92EE;'>#结果公布#</a>, objectTitle=1569项不予受理！2022年国自然基金初审结果公布, objectType=article, longId=725647, objectId=2a25e2564746, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a25e2564746, replyNumber=0, likeNumber=83, createdTime=2023-03-26, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a25e2564746, moduleTitle=1569项不予受理！2022年国自然基金初审结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2a25e2564746)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

结果公布

2020-05-29

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

NEJM Evid：固定疗程的伊布替尼联合维奈克拉（Ibr+Ven）一线治疗慢性淋巴细胞白血病结果公布（GLOW研究）

2023-01-10

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

Nat Med：两项多格列艾汀的III期研究结果公布，降糖作用显著且长期持续

2022-07-25

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

猴痘病毒最新基因测序结果公布，近似于英国三年前毒株

2022-12-27

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

NEJM：艾伏尼布联合阿扎胞苷治疗IDH1突变AML的3期研究结果公布，患者获益显著

2023-02-21

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

JCO：阿美替尼对比吉非替尼对EGFR突变NSCLC一线治疗结果公布（AENEAS研究）

2022-09-15

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

Nature子刊：AAV病毒基因治疗艾滋病的首次临床试验结果公布

2022-11-12

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

JACC子刊：中山医院结构团队的两项中国原创器械研究结果公布

2022-08-13

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

AACR 2022：度伐利尤单抗和和曲美木单抗联合一线新辅助化疗治疗晚期卵巢癌患者的结果公布 (KGOG 3046/TRU-D)

2022-12-16

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

NEJM Evid：奥拉帕利联合阿比特龙治疗转移性前列腺癌结果公布（PROpel研究）

2023-01-16

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

全球植物源性COVID-19疫苗3期结果公布：对变异毒株总体效力为71%！

2022-07-01

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

全球首个二价新冠疫苗2/3期临床结果公布，有效性是当前新冠疫苗的2倍多，秋季开打

2022-06-22

医者仁心 (审核中...)

前往app查看评论内容

#结果公布#

Lancet microb：国产新冠mRNA疫苗临床I期结果公布，10个关键信息披露进展

2022-10-27

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

AACR 2022：第二代PARP1选择性抑制剂首次人体试验结果公布

2022-06-24

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

AACR 2022：第四代EGFR抑制剂BLU-945治疗晚期耐药的NSCLC早期结果公布

2022-04-23

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

公开通报：上百人被处理，涉及复旦、首医！35起医学科研诚信案件调查处理结果公布

2022-10-25

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

2021年国自然基金结果公布了！资助45681项！你中了吗？

2022-02-09

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

世界「人类故意感染新冠」试验结果公布！鼻腔注入病毒，大多数人3个月内自愈

2022-04-05

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

2021年8月6日简报：国内多地出现新增病例，无症状感染比例占1/3；FDA制订新冠疫苗加强针计划，中国承诺向国际出口20亿剂疫苗，多款疫苗真实世界研究结果公布

2022-02-10

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

Nutrition 2021速递：孕期保持健康的研究结果公布

2021-08-27

shanyongle (审核中...)

前往app查看评论内容

#结果公布#

1569项不予受理！2022年国自然基金初审结果公布

2023-03-26

科室
- - 订阅+
  - 更多科室
工具
服务